Form 4: Marinus Pharmaceuticals CFO Steven Pfanstiel Sells Shares to Cover Tax Obligations

CFO and COO of Marinus Pharmaceuticals, Steven Pfanstiel, sold 4,657 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Steven Pfanstiel, CFO and COO of Marinus Pharmaceuticals, sold 4,657 shares of common stock on August 5, 2024.
• The sale was executed to cover tax obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted-average price of $1.13.
• The transactions occurred at prices ranging from $1.11 to $1.16.
• Following the transaction, Pfanstiel directly owns 79,773 shares of Marinus Pharmaceuticals.
• The sale was conducted under a Rule 10b5-1 Plan adopted on May 16, 2022.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The sale is related to tax obligations and executed under a pre-arranged plan, suggesting it's not necessarily indicative of a negative outlook on the company.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which is often viewed as a proactive measure to avoid insider trading concerns.

Industry Context

Sales by company executives are a normal part of corporate activity. It is important to consider the context of the sale, such as the use of a 10b5-1 plan, to understand the motivation behind the transaction.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders due to the potential for slight price fluctuations.

Key Dates

Keywords

Marinus Pharmaceuticals, MRNS, Steven Pfanstiel, CFO, COO, stock sale, Form 4, Rule 10b5-1, insider trading, restricted stock units, tax obligations